Donald E. Morel Jr.
Known title: DirectorCIK: 0001213306
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
IART May Be 48% Undervalued Based on Cash Flow Analysis. A recent Yahoo analysis suggests Integra LifeSciences shares could be trading about 48% below their intrinsic value when cash flow is considered. The stock sits near its 13‑touch support level of $9.10 and an RSI of 41.6, indicating neither overbought nor oversold conditions. The average analyst target is $19.56, well above the current price, highlighting a potential valuation gap. This analysis may prompt a closer look at the company’s cash flow performance relative to market expectations.
Transaction History
| STVN | ▼ Sell | Open Market | 1,493 | $26K | 6/15/2026 | View on chart |
| STVN | ▲ Buy | Grant | 4,975 | $0 | 6/12/2026 | View on chart |
| IART | ▲ Buy | Grant | 3,456 | $0 | 5/13/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Stevanato Group joins Ensera alliance with medical device partners
Stevanato Group has joined a new alliance network led by Ensera, alongside partners like SHL Medical and Ypsomed. This move aims to strengthen collaboration within the medical device supply chain. The stock is currently trading near its support level, with an average analyst target of $24.68.
Stevanato Group joins Ensera alliance with medical device partners. Stevanato Group has joined a new alliance network led by Ensera, alongside partners like SHL Medical and Ypsomed. This move aims to strengthen collaboration within the medical device supply chain. The stock is currently trading near its support level, with an average analyst target of $24.68.